Allogene Therapeutics, Inc. (ALLO) Profit Margins
Over the twelve months to 2026-06-30, Allogene Therapeutics, Inc. (ALLO) had operating margin -3886.1%, net margin -3566.7%, free cash flow margin -2489.8%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALLOAllogene Therapeutics, Inc.Follow ALLO — free
—
Price chart with a free account
- Market cap
- 431.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating margin | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — | -3886.1% | |
| Net margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — | -3566.7% | |
| FCF margin | -186.1% | -150801.3% | -264524.2% | -970450.0% | — | -2489.8% |
USD billions · SEC XBRL
Allogene Therapeutics, Inc. — questions
- What is Allogene Therapeutics, Inc.'s operating margin?
- -3886.1% over the twelve months to 2026-06-30.
- What is Allogene Therapeutics, Inc.'s net profit margin?
- -3566.7% over the twelve months to 2026-06-30.
Every figure on this page comes from Allogene Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.